| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02663674 Details | 2019-07-05 Interventional | 4 | 72 | Fluconazole Coccidioidomyco… Coccidiosis Pneumonia | Study terminated due to lack of feasibility of study design. The study terminated early due to low enrollment rates. When the study was stopped, 72 of a planned 1000 participants were enrolled and randomized; therefore, formal comparisons of the endpoints are not included. | |||
| NCT02630186 Details | 2019-07-05 Interventional | 1/2 | 3 | Atezolizumab Carcinoma, Non-… Lung Neoplasms Non-small Cell … | The study terminated before Phase 1 was completed. This study was reprioritized within the
rociletinib development program. This study was terminated early which lead to small number of subjects analyzed. The study did not reach the target number of participants needed to achieve target power and statistically reliable results. | |||
| NCT02496715 Details | 2019-07-05 Interventional | 3 | 0 | Fluticasone Salmeterol Xina… Xhance Asthma | Development terminated. - | |||
| NCT02435303 Details | 2019-07-05 Interventional | 2/3 | 2 | Sildenafil Citr… Hypertension Hypertension, P… Diseases of Mit… | Number of candidates for this study is expected to be too small. - | |||
| NCT02065336 Details | 2019-07-05 Interventional | 2 | 58 | Chlorpheniramin… Entecavir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | Company decision to discontinue trial The ARC-520 Injection development program was terminated early for regulatory and business reasons secondary to findings occurring in a non-clinical toxicology study. Program termination was not due to safety findings in humans. | |||
| NCT01760980 Details | 2019-07-05 Interventional | 1 | 0 | Exemestane Healthy | Development halted by management - | |||
| NCT01601093 Details | 2019-07-05 Interventional | 2 | - | Cefoperazone Sulbactam Sulperazone Communicable Di… Infections Respiratory Tra… Urinary Tract I… | other project got priority - | |||
| NCT01912872 Details | 2019-07-02 Interventional | 4 | 112 | Budesonide Formoterol Fuma… Omalizumab Asthma Severe IgE-medi… | Termination was due to identified errors in data management handling after an internal audit by
the sponsor performed by third party. - | |||
| NCT00759642 Details | 2019-07-01 Interventional | 2 | 33 | Lapatinib Breast Neoplasm… Metastatic Brea… | IRB decision - | |||
| NCT02696954 Details | 2019-06-28 Interventional | 1/2 | 17 | Amodiaquine Artemether Artemether, Lum… Lumefantrine Primaquine Drug Combinatio… Healthy Pharmacokinetic | - - | |||
| NCT02932488 Details | 2019-06-27 Interventional | 1 | 17 | Sumatriptan Healthy Volunte… | Pilot study with sumatriptan found no significant changes in the primary outcome parameter
(change in CBF) - | |||
| NCT01632566 Details | 2019-06-27 Interventional | 1 | 39 | Celecoxib LY3031207 Simvastatin Healthy Volunte… | Elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in some
participants. Lilly voluntarily discontinued dosing of LY3031207 for all participants in LBCB because of early discontinuation criteria being met. Data for some endpoints (including blood pressure and Japanese comparison) were incomplete for the planned analyses. | |||
| NCT01111188 Details | 2019-06-27 Interventional | 1 | 20 | Bortezomib Palbociclib Lymphoma Lymphoma, Mantl… Mantle Cell Lym… | - - | |||
| NCT00148616 Details | 2019-06-27 Interventional | 3 | 13 | Memantine Cognitive Dysfu… Schizophrenia Chronic Schizop… | - - | |||
| NCT00148590 Details | 2019-06-27 Interventional | 3 | 24 | Memantine Cognitive Dysfu… Schizophrenia | - - | |||
| NCT02759315 Details | 2019-06-26 Interventional | 2 | [1 Refs] | 160 | Ruzasvir Uprifosbuvir Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… | The study was terminated based on review of Phase 2 efficacy data - | ||
| NCT02367352 Details | 2019-06-26 Interventional | 1 | 9 | Paclitaxel Small Cell Lung… Advanced Solid … Ovarian Cancer Small Cell Lung… | Sponsor's decision - | |||
| NCT02343575 Details | 2019-06-26 Interventional | 4 | 3 | Haloperidol Haloperidol dec… Valproic Acid Delirium Hyperkinesis Psychomotor Agi… Hyperactive Del… Mixed Delirium | We did not recruit the research assistant and terminated the study The study terminated early and did not meet its planned sample size of 30 participants, leading to a small number of subjects analyzed. | |||
| NCT01892345 Details | 2019-06-26 Interventional | 3 | [1 Refs] | 143 | Eculizumab Neuromyelitis O… Neuromyelitis O… | - After rigorous review of blinded study data, the Sponsor terminated the study at 23 adjudicated events, not the protocol-specified 24. This was not driven by safety or efficacy concerns, but rather by uncertainty in estimating final event occurrence. | ||
| NCT02966730 Details | 2019-06-25 Interventional | 1 | 2 | Ibrutinib Lymphoma Lymphoma, Folli… Follicular Lymp… Follicular Lymp… Follicular Lymp… Follicular Lymp… | Lack of accrual - |